Antihypertensive therapy in type 2 diabetes: Implications of the Appropriate Blood Pressure Control in Diabetes (ABCD) trial

American Journal of Cardiology

Volumn 82, Issue 9 SUPPL. 1, 1998, Pages 9-14

  Estacio, Raymond O ^b   Schrier, Robert W ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; NISOLDIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; ADULT; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, TYPE 2; ENALAPRIL; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NISOLDIPINE; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 0032511849     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00750-4     Document Type: Article

References (40)

1. National Center for Health Statistics. Advance report of final mortality statistics, 1986. Monthly Vital Statistics Report 1988;37:1-56.
2. Panzram G. Mortality and survival in type 2 (non-insulin-dependent diabetes) diabetes mellitus. Diabetologia 1987;30:123-131.
3. Moss SE, Klein R, Klein BE. Cause-specific mortality in a population-based study of diabetes. Am J Public Health 1991;81:1158-1162.
4. Epstein M. Diabetes and hypertension: the bad companions. J Hypertens 1997;15(suppl 2):S55-S62.
5. American Diabetes Association. Clinical Practice Recommendations, 1998. Diabetes Care 1998:21:suppl 1.
6. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997:157:2413-2416.
7. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-677.
8. ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-682.
9. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-1122.
10. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-1435.
11. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricle ejection fractions. N Engl J Med 1992;327:685-691.
12. Cohn J. Drug therapy: the management of chronic heart failure. N Engl J Med 1996;335:490-498.
13. Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med 1995;155:829-837.
14. Parving HH. Effects of ACE inhibitors on renal function in incipient and overt diabetic nephropathy. J Diabet Compile 1996;10:133-135.
15. Lewis EJ. Angiotensin-converting enzyme inhibition in type I diabetic nephropathy. Contrib Nephrol 1996;118:206-213.
16. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996;334:939-945.
17. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996;156:286-289.
18. Parving HH, Rossing P, Hommel E, Smidt UM. Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years experience. Am J Kidney Dis 1995;26:99-107.
19. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Giffor N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-652.
20. Savage S, Johnson N, Estacio RO, Feig PU, MacCarthy PE, Lukken NJ, Ziegler R, Schrier RW. The ABCD (Appropriate Blood Pressure Control in Diabetes) Trial. Rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes. Online J Clin Trials 1993;2:doc 104.
21. Janka HU, Dirschedl P. Systolic blood pressure as a predictor for cardiovascular disease in diabetes. A 5-year longitudinal study. Hypertension 1985;7(suppl II):II-90-II-94.
22. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart study. Diabetes Care 1992;15:820-825.
23. Kuusisto J, Leena M, Pyorala K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994;43:960-967.
24. Epstein M. Calcium antagonists in the management of hypertension. In: Epstein M, ed. Calcium Antagonist in Clinical Medicine. Philadelphia: Hanley Belfus, 1992:213-230.
25. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-625.
26. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-1331.
27. Michels KB, Rosner BA, Manson JE, Stampfer MJ, Walder AM, Willett WC, Hennekens CH. Prospective study of calcium channel blocker use, cardiovascular disease, and total mortality among hypertensive women. The Nurses' Health Study. Circulation 1998:97:1540-1548.
28. Epstein M. The calcium antagonist controversy: the emerging importance of drug formulation as a determinant of risk. Am J Cardiol 1997;79:9-19.
29. Glasser SP, Ripa S, Garland WT, Weiss R, Nademanee K, Singh S, Bittar N. Antianginal and antiischemic efficacy of monotherapy extended-release nisoldipine (Coat Core) in chronic stable angina. J Clin Pharmacol 1995;35:780-784.
30. Heublein B, Amende I, Blanke PM, Baunack-Frost AR, Breuer HW. Nisoldipine versus isosorbide dinitrate in coronary heart disease: result of a double-masked study. Clin Ther 1996;18:448-459.
31. Weinstein DB, Heider JG. Protective action of calcium antagonists in atherosclerosis and experimental vascular injury. Am J Hypertens 1989;2:205-212.
32. Lichtlen PR, Hugenholtz PG, Raffenbeul W, Hecker H, Jost S, Deckers JW, on behalf of the INTACT Group. Retardation of angiographic progression of coronary artery disease by nifedipine: results of the International Nifedipine Trial on Anti-atherosclerotic Therapy (INTACT). Lancet 1990;335:1109-1113.
33. Waters D, Lesperance J. Interventions that beneficially influence the evolution of coronary atherosclerosis: the case for calcium channel blockers. Circulation 1992;88(suppl 6):111-116.
34. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin inpatients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351: 1755-1762.
35. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze G, Birkenhäger W, Bulpitt C, De Leeuw P, Dollery CT, Fletcher A, Forette F, Leonetti G, Nachey C, O'Brien E, Rosenfeld J, Rodicio J, Tuomilehto J, Zanchetti A. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-764.
36. Cody RJ. The integrated effects of angiotensin II. Am J Cardiol 1997; 79(suppl):9-11.
37. Vaughan DE. The renin-angiotensin system and fibrinolysis. Am J Cardiol 1997;79(suppl):12-16.
38. McVeigh GE, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR, Andrews JW, Hayes JR. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992;35:771-776.
39. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Luscher TF, Kubaner MI, Haber HE, Uprichard AC, Pepine CJ, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND Study. Circulation 1996;94:258-265.
40. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JTJ, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996;9:342-360.